Cargando…

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma

PURPOSE: Various blood cell parameters have been identified as predictive markers of tumor responses and the survival of patients with cancer treated with immune checkpoint inhibitors. The purpose of this study is to assess the ability of various blood cell parameters to predict therapeutic effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamai, Yoichi, Emi, Manabu, Ibuki, Yuta, Kurokawa, Tomoaki, Yoshikawa, Toru, Ohsawa, Manato, Hirohata, Ryosuke, Kitasaki, Nao, Okada, Morihito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103711/ https://www.ncbi.nlm.nih.gov/pubmed/37065776 http://dx.doi.org/10.2147/OTT.S404926

Ejemplares similares

Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma
por: Ohsawa, Manato, et al.
Publicado: (2023)

Recurrent esophageal adenocarcinoma derived from ectopic gastric mucosa: A case report
por: Kitasaki, Nao, et al.
Publicado: (2022)

Risk factors for aortoesophageal fistula in cT4b esophageal squamous cell carcinoma after definitive radiation therapy
por: Hirohata, Ryosuke, et al.
Publicado: (2023)

Thoracoscopic double-flap reconstruction for esophagogastric junction cancer: A case report
por: Ohsawa, Manato, et al.
Publicado: (2020)

Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma
por: Ibuki, Yuta, et al.
Publicado: (2020)

Three-step surgical treatment of aortoesophageal fistula after thoracic endovascular aortic repair: A case report
por: Kamigaichi, Atsushi, et al.
Publicado: (2019)

Role of FDG-PET/CT in prediction of pathological tumor response and survival after trimodality therapy for esophageal squamous cell carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2015)

Emergency escape surgery for a gastro-bronchial fistula with respiratory failure that developed after esophagectomy
por: Ibuki, Yuta, et al.
Publicado: (2014)

Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report
por: Hamai, Yoichi, et al.
Publicado: (2012)

Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
por: Ochi, Masanori, et al.
Publicado: (2020)

Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma
por: Murakami, Yuji, et al.
Publicado: (2018)

Leukocyte Telomeric G-Tail Length Shortening Is Associated with Esophageal Cancer Recurrence
por: Han, Jiayan, et al.
Publicado: (2022)

Diffuse alveolar hemorrhage with nivolumab monotherapy
por: Shannon, Vickie R., et al.
Publicado: (2020)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma
por: Grzegorczyk, Aleksandra, et al.
Publicado: (2023)

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy
por: Inagaki, Chiaki, et al.
Publicado: (2023)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumors
por: Kawahara, Takashi, et al.
Publicado: (2022)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
por: Hasegawa, Hirotaka, et al.
Publicado: (2022)

Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer
por: Inoue, Yusuke, et al.
Publicado: (2020)

Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
por: Khunger, Monica, et al.
Publicado: (2018)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
por: Jiang, Meilin, et al.
Publicado: (2020)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
por: Hinata, Nobuyuki, et al.
Publicado: (2020)

Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3
por: Chin, Keisho, et al.
Publicado: (2022)

Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

Nivolumab in the treatment of malignant melanoma: review of the literature
por: Mashima, Emi, et al.
Publicado: (2015)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019)

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL)
por: Kagimoto, Atsushi, et al.
Publicado: (2021)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
por: Glutsch, Valerie, et al.
Publicado: (2019)

Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
por: Watanabe, Hayato, et al.
Publicado: (2021)

Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)
por: Takahashi, Masanobu, et al.
Publicado: (2020)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Pathological complete response of multiple liver metastases from colon cancer successfully treated with conversion surgery: A case report
por: Kitasaki, Nao, et al.
Publicado: (2023)

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
por: George, Daniel J, et al.
Publicado: (2022)

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
por: Voss, Martin H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kv0kc3oj48i41ge4tckimsc78r